Drug/device combinations for local drug therapies and infection prophylaxis.
Combination devices-those comprising drug releasing components together with functional prosthetic implants-represent a versatile, emerging clinical technology promising to provide functional improvements to implant devices in several classes. Landmark antimicrobial catheters and the drug-eluting stent have heralded the entrance, and significantly, routes to FDA approval, for these devices into clinical practice. This review describes recent strategies creating implantable combination devices. Most prominent are new combination devices representing current orthopedic and cardiovascular implants with new added capabilities from on-board or directly associated drug delivery systems are now under development. Wound coverings and implantable sensors will also benefit from this combination enhancement. Infection mitigation, a common problem with implantable devices, is a current primary focus. On-going progress in cell-based therapeutics, progenitor cell exploitation, growth factor delivery and advanced formulation strategies will provide a more general and versatile basis for advanced combination device strategies. These seek to improve tissue-device integration and functional tissue regeneration. Future combination devices might best be completely re-designed de novo to deliver multiple bioactive agents over several spatial and temporal scales to enhance prosthetic device function, instead of the current 'add-on' approach to existing implant device designs never originally intending to function in tandem with drug delivery systems.
Wu
Peng
P
Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872, USA.
Grainger
David W
DW
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage; D001458:Bandages; D001672:Biocompatible Materials; D002405:Catheterization, Central Venous; D002557:Cerebrospinal Fluid Shunts; D003907:Dexamethasone / Q000008:administration & dosage; D016503:Drug Delivery Systems; D004343:Drug Implants; D006133:Growth Substances / Q000008:administration & dosage; D006801:Humans; D008422:Materials Testing; D019736:Prostheses and Implants; D016459:Prosthesis-Related Infections / Q000517:prevention & control*; D012038:Regeneration; D015607:Stents; D014546:Urinary Catheterization
D000890:Anti-Infective Agents; D001672:Biocompatible Materials; D004343:Drug Implants; D006133:Growth Substances; D003907:Dexamethasone